Perrigo/$PRGO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Perrigo
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Ticker
$PRGO
Sector
Primary listing
NYSE
Employees
8,379
Headquarters
Dublin, Ireland
Website
Perrigo Metrics
BasicAdvanced
$2.1B
-
-
-
$1.15
7.68%
Price and volume
Market cap
$2.1B
52-week high
$30.93
52-week low
$15.05
Average daily volume
2.3M
Dividend rate
$1.15
Financial strength
Profitability
Management effectiveness
Valuation
Dividend yield (TTM)
7.59%
Forward dividend yield
7.68%
Growth
What the Analysts think about Perrigo
Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Bulls say / Bears say
In Q1 2025, Perrigo expanded adjusted operating margin by 550 basis points to 14.0%, driven by Project Energize cost savings and margin management, marking a notable turnaround from the prior year’s loss-making quarter (PR Newswire).
The sale of Perrigo’s dermacosmetics business to Kairos Bidco for up to €327 million in July 2025 will sharpen the company’s focus on core self-care brands and inject €300 million in upfront cash, strengthening its financial flexibility (Fierce Pharma).
The Nutrition category, anchored by infant formula, delivered 16% net sales growth in Q1 2025, demonstrating recovery momentum in a key segment after prior regulatory and supply disruptions (Investor.Perrigo.com).
Net sales in Q2 2025 declined 0.9% year-over-year to $1.06 billion, reflecting continued top-line pressure amid challenging market consumption trends and the impact of prior divestitures (PR Newswire).
Adjusted gross margin in Q2 2025 fell 250 basis points to 38.1%, driven by divested businesses, isolated infant formula production variability, and lower plant overhead absorption, pointing to margin headwinds ahead (PR Newswire).
Perrigo expects a gross increase to global cost of goods sold of $50 million–$60 million in full-year 2025 due to rising tariff and inflationary pressures, which may further compress margins if pricing and insourcing actions underperform (RTTNews).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Perrigo Financial Performance
Revenues and expenses
Perrigo Earnings Performance
Company profitability
Perrigo News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Perrigo stock?
Perrigo (PRGO) has a market cap of $2.1B as of November 06, 2025.
What is the P/E ratio for Perrigo stock?
The price to earnings (P/E) ratio for Perrigo (PRGO) stock is 0 as of November 06, 2025.
Does Perrigo stock pay dividends?
Yes, the Perrigo (PRGO) stock pays dividends to shareholders. As of November 06, 2025, the dividend rate is $1.146 and the yield is 7.68%. Perrigo has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Perrigo dividend payment date?
The next Perrigo (PRGO) dividend payment is scheduled for December 16, 2025.
What is the beta indicator for Perrigo?
Perrigo (PRGO) does not currently have a Beta indicator.